Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy

NCT07640191 | Recruiting DMC

• 1 other identifier: CLN-000001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to assess the safety and performance of the iVEAcare Neuromodulation System for the treatment of drug-resistant epilepsy. The main questions it aims to answer are: What medical problems do participants have when being implanted with and using the iVEAcare system? Does the iVEAcare neurostimulator reduce seizure frequency and severity in patients with drug-resistant epilepsy? Does the iVEAcare neurostimulator improve quality of life in patients with drug-resistant epilepsy? All participants will be implanted with an iVEAcare neurostimulator, and researchers will look at whether any medical problems are caused by the implant procedure or device, and how stimulation changes seizure frequency and severity and participant quality of life compared to when the participant enrolled. Participants will: Be implanted with an iVEAcare device. Visit the clinic 1-month, 3-months, 6-months, 1-year, 18-months and then annually through 5 years where they will be asked to answer questionnaires about their seizures and quality of life. Keep a diary of the number of seizures they have each day.

Conditions

Drug Resistant Epilepsy

Outcome Measures

Primary Outcomes (1)

• iVEAcare Neuromodulation System Safety

  assessment of the rate of serious treatment-related (procedure, device- and/or therapy-related) adverse events

  30 days

Secondary Outcomes (8)

• Seizure Frequency

  3 months

• Seizure Severity

  3 months

• Change in Quality of Life

  3 months

• Participant View of Overall Status

  6 months

• Clinician View of Overall Status

  6 months

Study Arms (1)

iVEAcare implant

EXPERIMENTAL

Implanted with an iVEAcare Neuromodulation System

Device: iVEAcare Neuromodulation System

Interventions

iVEAcare Neuromodulation System DEVICE

iVEAcare Neuromodulation System implant

iVEAcare implant

Eligibility Criteria

• Age: 4 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 4 to 75 years.
• Focal (partial) onset seizures (with or without secondary generalization) or generalized seizures that are refractory to anti-seizure medications.
• A minimum of 4 seizures per month averaged over the 90 days prior to enrollment.
• Participant is diagnosed with Drug Resistant Epilepsy (DRE) - Failure to achieve seizure control with adequate trials of two or more tolerated anti-seizure medications.
• Anti-seizure medications must be at a steady state for a minimum of 30 days and remain stable through the 6-month post-activation study visit. Rescue medications may still be used as necessary

You may not qualify if:

• Unsuitable for iVEAcare Neuromodulation System implant surgery.
• Deteriorating neurologic or other deteriorating medical conditions.
• Previous left vagotomy (left vagus nerve cut to treat another disorder).
• A condition currently requiring diathermy treatment anywhere in their body (short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy).
• Known vagal neuropathy, or other reasons that the left vagus nerve is not appropriate for implant.
• Vocal cord paralysis.
• Prior therapeutic brain surgery for epilepsy within 6 months prior to the baseline visit.
• Currently implanted with an Implantable Cardiac Defibrillator (ICD), pacemaker, Deep Brain Stimulator (DBS), Responsive Neurostimulator (RNS), Spinal Cord Stimulator (SCS), Peripheral Nerve Stimulator (PNS), Sacral Nerve Stimulator (SNS), carotid baroreceptor stimulator, cochlear implant, or currently using external stimulation devices such as a Transcutaneous Electrical Nerve Stimulator (TENS). Note: Participants who currently have a commercially available VNS system for drug-resistant epilepsy and are eligible for a generator replacement (due to nearing end of life) can receive the iVEAcare Implantable Pulse Generator (IPG) alone if their existing lead has been confirmed to be functioning properly preoperatively and intraoperatively.
• Pregnant or planning to be pregnant in the next 12 months. .
• Any active malignant disease (not including skin cancer).
• Any active infection in the vicinity of the implant site or any systemic infection.
• Poorly controlled diabetes (Type I or Type II) determined by HbA1c \>8% (or \> 64 mmol/mol

Sponsors & Collaborators

• iVEAcare: lead

Study Sites (2)

The Mater

South Brisbane, Queensland, 4101, Australia

RECRUITING

The Alfred Hospital

Melbourne, Victoria, 3004, Australia

RECRUITING

MeSH Terms

Conditions

Drug Resistant Epilepsy

Condition Hierarchy (Ancestors)

Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Terence O'Brien, MD

  The Alfred Hospital and Monash University

  STUDY CHAIR

Central Study Contacts

VP, Clinical Affairs

CONTACT

+1 651 728 4832; clinical@iveacare.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2026
• First Posted: June 10, 2026
• Study Start: July 1, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2032
• Last Updated: July 17, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

AU (2)